Context Therapeutics Inc. 8-K

What Happened

• Context Therapeutics Inc. announced on March 23, 2026 that it updated its corporate presentation for use with investors, analysts and others and filed that presentation as Exhibit 99.1 to a Current Report on Form 8-K (Accession No. 0001628280-26-020517). The disclosure was made under Item 7.01 (Regulation FD Disclosure) and referenced in Item 8.01 (Other Events). The report was signed by CEO Martin A. Lehr.

Key Details

• Filing date: March 23, 2026.
• Exhibit filed: Exhibit 99.1 — Context Therapeutics Inc. Corporate Presentation (March 2026).
• Specific incorporation: Slides 15 and 32 of Exhibit 99.1 are expressly incorporated by reference into Item 8.01.
• Report signed by: Martin A. Lehr, Chief Executive Officer.

Why It Matters

• An updated corporate presentation can contain refreshed information on strategy, pipeline, milestones, or corporate initiatives that investors and analysts use to evaluate the company; Context officially filed the updated slides so market participants can review them.
• The Item 7.01 Regulation FD disclosure and the formal 8-K filing ensure the company is publicly disclosing the materials used in investor communications. The filing does not report financial results, executive changes, or a merger—investors should review Exhibit 99.1 for any substantive content on operations or clinical progress.